A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia

This trial tested the safety and efficacy of a regimen consisting of hydroxyurea followed by azacitidine, 75 mg/m(2) for 7 days, and gemtuzumab ozogamicin, 3 mg/m(2) on day 8, in older patients with newly diagnosed acute myeloid leukemia. Those achieving a complete remission received 1 consolidation...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Nand, Sucha, Othus, Megan, Godwin, John E., Willman, Cheryl L., Norwood, Thomas H., Howard, Dianna S., Coutre, Steven E., Erba, Harry P., Appelbaum, Frederick R.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2013
Matèries:
Clinical Trials and Observations
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3829116/
https://ncbi.nlm.nih.gov/pubmed/24092933
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-06-506592
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars